Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Imidazoline childproof package deadline extended; FDA wants to define food allergen thresholds; Danone cuts workforce in Europe; Primatene Mist bill voted down in the house; CARU urges WhoNu? ad off kids TV; Bayer recalls Bronkaid; Tate & Lyle to develop Nandi Proteins food ingredient; more news In Brief.

You may also be interested in...



Imidazoline Childproof Packaging Deadline Extended Six Months, Potentially More

The Consumer Product Safety Commission followed its staff’s recommendation to extend the deadline for six months, through May 10, 2105, and to consider requests for additional six-month extensions on a case-by-case basis.

Imidazoline Childproof Packaging Deadline Extended Six Months, Potentially More

The Consumer Product Safety Commission followed its staff’s recommendation to extend the deadline for six months, through May 10, 2105, and to consider requests for additional six-month extensions on a case-by-case basis.

Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory

Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel